StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3035% above fair value
$8.64−0.27 (-3.03%)

Close on Nov 20, 2026Market cap $737.11MP/E –Yield –

Monte Rosa Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Monte Rosa Therapeutics

Monte Rosa Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Monte Rosa Therapeutics figures

See a number that looks wrong?